ArriVent BioPharma
AVBP
53 hedge funds and large institutions have $389M invested in ArriVent BioPharma in 2024 Q1 according to their latest regulatory filings, with 53 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
68.37% more ownership
Funds ownership: 0% → 68.37% (+68%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HA
HHLR Advisors
Grand Cayman,
Cayman Islands
|
+$79.3M |
| 2 |
O
OrbiMed
New York
|
+$61.1M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$39.3M |
| 4 |
OCA
Octagon Capital Advisors
New York
|
+$39.2M |
| 5 |
SI
Sofinnova Investments
Menlo Park,
California
|
+$34.2M |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
MLICM
51
Metropolitan Life Insurance Company (MetLife)
New York
| $10.1K | +$11.4K | +567 | New |
|
|
AB
52
Amalgamated Bank
New York
| $10K | +$10.9K | +540 | New |
|
53
Royal Bank of Canada
Toronto,
Ontario, Canada
| $7K | +$7.44K | +369 | New |
|
AVBP Hedge Fund Activity: Q1 2024 in Review
53 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in ArriVent BioPharma (AVBP) for Q1 2024, worth a combined $389M.
Buyers outnumbered sellers: 53 funds opened new AVBP positions and 0 closed out — a net gain of 53 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was HHLR Advisors, opening a new position worth an estimated $79.3M.
- 53 institutional investors held ArriVent BioPharma (AVBP) as of Q1 2024, up from 0 in Q4 2023.
- Funds reported $389M of ArriVent BioPharma stock for Q1 2024.
- 53 funds opened new ArriVent BioPharma positions in Q1 2024 and 0 closed out, a net change of +53 holders.
- The largest ArriVent BioPharma buyer in Q1 2024 was HHLR Advisors, an estimated $79.3M added.
Based on aggregated 13F filings for Q1 2024.